Efficacy, safety, and vascular endothelial function improvement of enalapril maleate-folic acid tablets in H-Type hypertension.

To explore the clinical application value of Enalapril Maleate (EM)-Folic Acid (FA) Tablets in the treatment of H-type hypertension (HTHT), with a focus on evaluating its therapeutic efficacy, safety, and regulatory effects on vascular endothelial function. A retrospective analysis was conducted on 127 HTHT patients treated between March 2022 and January 2025. Patients were allocated into two groups: a control group (n=60) receiving EM monotherapy and a research group (n=67) receiving the EM-FA therapy. This study analyzed: ① overall therapeutic outcomes; ② blood pressure control; ③ stroke incidence; ④ drug-related adverse events; ⑤ lipid metabolism; ⑥ homocysteine (Hcy) levels; ⑦ vascular endothelial function; ⑧ serum inflammatory markers; and ⑨ hemorheological parameters. Compared with the control group, the research group exhibited superior post-treatment outcomes. Specifically, overall treatment efficacy was improved; blood pressure control was more effective; lipid profiles improved significantly; Hcy levels decreased more significantly; vascular endothelial function was better restored; inflammatory factor levels decreased more substantially; hemorheological parameters were optimized; and the incidences of stroke and drug-related adverse events were notably reduced. EM-FA Tablets provide significant therapeutic benefits in managing HTHT, with enhanced safety and notable improvements in vascular endothelial function, underscoring their potential for widespread clinical application.